Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.
about
Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosusA review of gastrointestinal manifestations of systemic lupus erythematosus.Cyclophosphamide for the treatment of systemic lupus erythematosus.Assessment of bone mineral density by dual x-ray absorptiometry in dermatological patients treated by corticosteroids.Pharmacotherapy for uveitis: current management and emerging therapy.Combination therapy in autoimmune disease: vasculitis.The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.An unusual cause of bilateral ophthalmoplegia.Central nervous system lupus: a clinical approach to therapy.Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy.Lupus nephritis: induction therapy.Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review.Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.Noninfectious immune-mediated uveitis and ocular inflammation.Mesenteric vasculitis in children with systemic lupus erythematosus.Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study.Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.The NIH pulse cyclophosphamide regime: the end of an era?First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK.Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.Multidrug resistance transporter-1 and breast cancer resistance protein protect against ovarian toxicity, and are essential in ovarian physiology.
P2860
Q28269798-25E36A0A-78F8-4A06-B22F-942860963595Q33759553-0762949C-88F4-4618-A669-6866D0A8E5F5Q34226984-A2624FA0-4047-41A3-9768-3107419D8644Q34250362-FC2FEEF1-C824-4D13-BF18-4FFDFAA90B5FQ34274075-8CE87F9B-275C-4E41-A477-8CBD8DEC5DAEQ34309769-EE1823E2-7E13-4EA1-B17E-8432C5E355E1Q34381902-244E42D2-369B-4287-A58C-D3C4895A52BEQ34535692-779B5392-D19A-4991-A102-A83974269A0DQ35625240-178928D4-D29C-422B-8D70-77154DBDA288Q35722478-F72E8A26-F5F3-47CB-AAF5-68A27360BD79Q36085856-53F4F228-3733-4C0D-80F5-FB8F8853BBABQ38101015-1389B296-3D6C-482C-98B7-912B09809584Q38136748-B55263F2-5201-4389-8310-C83ABDE281FAQ38149856-B84FC89C-3CB8-4D03-903B-CE1C48B29D2EQ38171373-A40F7AFE-6E6A-4321-BD0C-4B4F3439B0EEQ38357995-D0A954BA-6EDB-46BD-880F-5D82750D9899Q40183545-FEF62101-04CE-48FC-A76D-192F84EB1919Q40748681-57F19682-A6ED-4E01-AD37-8C0FDFA8185FQ44761101-3E38A14D-49DC-4DBB-90BC-FC43F453736AQ45047982-B95BBD0B-C757-4F20-B708-EF77E6538619Q46934931-3E3CCE58-05BB-4DEA-AD35-DBB7D15A9AA0Q47913418-1270EE52-2F91-4D58-B54C-8EF3E80376BBQ48528733-5C42E6C1-2E74-4986-86DB-7B6771DFC279
P2860
Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.
description
1997 nî lūn-bûn
@nan
1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Immunosuppressive treatment in ...... intravenous cyclophosphamide.
@ast
Immunosuppressive treatment in ...... intravenous cyclophosphamide.
@en
type
label
Immunosuppressive treatment in ...... intravenous cyclophosphamide.
@ast
Immunosuppressive treatment in ...... intravenous cyclophosphamide.
@en
prefLabel
Immunosuppressive treatment in ...... intravenous cyclophosphamide.
@ast
Immunosuppressive treatment in ...... intravenous cyclophosphamide.
@en
P2093
P2860
P356
P1476
Immunosuppressive treatment in ...... intravenous cyclophosphamide.
@en
P2093
Fernandes AP
Martin-Suarez I
P2860
P304
P356
10.1136/ARD.56.8.481
P407
P577
1997-08-01T00:00:00Z